CSIMarket


Repligen Corp  (RGEN)
Other Ticker:  
 


 

Repligen Corp

RGEN's Financial Statements and Analysis



Repligen Corp reported in the third quarter of 2023 net earnings per share of $0.32 a decrease by -54.93 % year on year from $0.71 and decline of -8.57 % from $0.35 earned in II. Quarter (Jun 30 2023).


third quarter of 2023
Earnings Per Share Revenues
$ 0.32 $  141 Mill
$-0.39     -54.93 % $-60M     -29.66 %



Repligen's Revenue fell by -29.66 % in third quarter of 2023 (Sep 30 2023) year on year, to $141 million and declined by -11.29 % sequentially.


Repligen is

More on RGEN's Income Statement



Repligen's net income of $18.172 million in the third quarter of 2023 decreased by -55.03 % from net earnings of $40.405 million achieved in III. Quarter a year ago.

Sequentially net earnings fell by -9.43 % from net income of $20.064 million realized in previous quarter.

More on RGEN's Growth

Repligen Inventories
Inventories declined by -12.91 % to $211.37 million from III. Quarter a year ago, sequentially inventories fell by -12.25 %. RGEN's Cash flow In the third quarter of 2023 company's net cash flow was $27 million

More on RGEN's Cash flow Statement


Repligen Corp does not pay out common stock dividend.

In trailing twelve-month period Repligen Corp earned $ 2.58 cash per share, on a free-cash flow basis 126.66 % of net earning per share.

Book value grew by 1.85 % sequentially to $35.02 per share, 146.75% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 13.66 per share from $ 13.06.

Company repurchased 0.54 million shares or 0.94 % in Sep 30 2023.
Interest Coverage Ratio was 117.23. Debt Coverage Ratio was 0.45.

More on RGEN's Dividends

 Market Capitalization (Millions) 10,440
 Shares Outstanding (Millions) 57
 Total Debt (Millions $) 286
 Revenue (TTM) (Millions $) 670
 Net Income (TTM) (Millions $) 116
 Cash Flow (TTM) (Millions $) 107
 Capital Exp. (TTM) (Millions $) -28
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,170




Repligen Corp does not pay out common stock dividend.

In trailing twelve-month period Repligen Corp had $ 2.58 cash flow per share, on a free-cash flow basis 126.66 % of net earning per share.

Book value grew by 1.85 % sequentially to $35.02 per share, 146.75% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value grew to $ 13.66 per share from $ 13.06.

Company repurchased 0.54 million shares or 0.94 % in Sep 30 2023.
Interest Coverage Ratio was 117.23. Debt Coverage Ratio was 0.45.

More on RGEN's Balance Sheets

 Market Capitalization (Millions) 10,440
 Shares Outstanding (Millions) 57
 Total Debt (Millions $) 286
 Revenue (TTM) (Millions $) 670
 Net Income (TTM) (Millions $) 116
 Cash Flow (TTM) (Millions $) 107
 Capital Exp. (TTM) (Millions $) -28
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,170
   


  News about Repligen Corp Earnings

Repligen Corp: Earnings Bolstered by $6.54 Million Tax Provisions Amid Slumping Profits



Repligen Corp, a prominent player in the Biotechnology and Pharmaceuticals industry, recently released its financial results for the July to September 30, 2023, reporting period. The results indicate a significant slump in net profit per share and revenue, contrasting with the industry's overall positive trend. This article aims to provide a comprehensive analysis of Repligen Corp's financial performance and its implications.
Financial Snapshot:
For the July to September 30, 2023 financial period, Repligen Corp experienced a notable decline in net profit per share. It dropped by 54.93% to $0.32 per share, compared to $0.71 per share in the same period the previous year. Additionally, net pr...

Repligen Corp Reports Significant Revenue Drop of 23.341% and Income Slump by 60.23% in Q2 2023, Falling Behind Biotech & Pharmaceuticals Sector

Revenue Demise Causes Slump in Income for Repligen Corp in Q2 2023
By [Author Name]
Investors were taken aback when Repligen Corp reported a significant decline in revenue for the second quarter of the 2023 earnings season, resulting in a slump in income. The company's revenue plummeted by a staggering -23.341%, dropping to $159.17 million from $207.63 million in the same period the previous year. This decline in revenue is in stark contrast to the overall growth seen in the Biotechnology and Pharmaceuticals sector.
The company also witnessed a decline in earnings per share (EPS), with only $0.35 per share recorded for Q2 2023 compared to $0.88 per share in the prior year. The drop in EPS further...

Very difficult fiscal period at Repligen Corp in the financial first quarter of 2023

Repligen Corp, a well-known Biotechnology and Pharmaceuticals company, has recently reported an 8.96% return on equity (ROE) for its first quarter in 2023. This figure is higher than RGEN's average ROE of 6.61%, which is a good sign. However, there are seven other companies in the same industry that have higher ROEs than Repligen Corp.
Although the company's overall ranking for ROE has improved in the first quarter of 2023, falling net income resulted in a reduction in ROE compared to the previous period. Repligen Corp has shown a market trend of declining income, with a -11.502% drop in revenue and a -37.04% decrease in income per...


Date modified: 2023-11-01T10:38:03+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com